ANI Pharmaceuticals, Inc.

NASDAQ:ANIP

Drug Manufacturers - Specialty & Generic

Healthcare
$71.47 -1.76%

-$1.42 today

Market cap
$1.62B
Beta
0.44
P/E (TTM)
18.5
EPS (TTM)
$4.29
52W Low $62.61High $99.50

Volume 0.29M

Average 0.35M

ANIP Investing Cash Flow

Net cash used in or generated by investments in assets, acquisitions, and securities.

ANI Pharmaceuticals, Inc.NASDAQ: ANIP

Investing Cash Flow · Q1 FY2026 · quarter ended Mar 2026

Investing cash flow declines year over year

Q1 FY2026 investing cash flow of $11.32M (cash outflow) fell 42.9% year over year, ahead of the -94.0% change in trailing-twelve-month investing cash flow. Sequentially, it rose 707.1% from the prior quarter. Over 3 fiscal years it compounded at +29.7% a year.

Context

  • Investing cash flow amounted to 3.9% of revenue in FY2025, down 62.0 pp from a year earlier.
  • Investing cash flow grew in size in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of -42.9% holds above the trailing-twelve-month pace of -94.0%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$11.32M+707.1% QoQ
Last fiscal yearDec 2025
-$34.32M-91.5% YoY
LTMMar 2026
-$25.8M-94.0% YoY
Investing Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-42.9%——
1 year-91.5%——
3-year CAGR+29.7%——
5-year CAGR——
10-year CAGR——

Investing Cash Flow history

USD · from the cash flow

Latest · FY2025
(34.32M) USD
Year-over-year change
+91.5%

Investing Cash Flow vs competitors

How ANIP compares with its peers on the latest reported figures

  • Peers report in different currencies, so investing cash flow is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -94.0% is the 8th highest of 10, against a peer median of -29.5%.
  • Investing cash flow amounts to 2.8% of revenue for ANIP, versus a peer median of 6.1%.
ANIP Competitors
Investing Cash Flow for ANIP and competitors
Company Period LTM YoY 3-year CAGR% of revenue
RDYDr. Reddy's Laboratories LimitedLTM Sep 2026₹31.03B INR-34.7%+19.5%9.4%
BHCBausch Health Companies Inc.LTM Jun 2026$601.71M USD+13.0%+25.2%5.5%
AMRXAmneal Pharmaceuticals, Inc.LTM Jun 2026$212.37M USD+161.8%-13.6%6.8%
AMPHAmphastar Pharmaceuticals, Inc.LTM Mar 2026$97.55M USD-24.8%+29.0%13.5%
VTRSViatris Inc.LTM Jun 2026$84.3M USD-105.8%—0.6%
COLLCollegium Pharmaceutical, Inc.LTM Mar 2026$52.23M USD-81.3%-52.0%6.6%
TEVATeva Pharmaceutical Industries LimitedLTM Jun 2026$38M USD-95.8%+4.0%0.2%
ANIPANI Pharmaceuticals, Inc.LTM Mar 2026$25.8M USD-94.0%+29.7%2.8%
HROWHarrow Health, Inc.LTM Mar 2026$23.45M USD-29.5%+46.3%8.7%
EOLSEvolus, Inc.LTM Mar 2026$8.28M USD+40.7%+42.2%2.7%
LFCRLifecore Biomedical, Inc.LTM Mar 2026$3.09M USD——2.3%
Peer median (excluding ANIP) —-29.5%+22.3%6.1%

Competitors are the stored peer set for ANIP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(42.6M)(47.9M)18.78M(18.52M)78.34M
Depreciation & Amortization47.25M59.65M59.79M67.73M91.42M
Deferred Income Tax(16.75M)(15.25M)(11.74M)(21.91M)14.24M
Stock-Based Compensation10.49M14.6M20.65M29.34M37.93M
Change in Working Capital(84K)(51.3M)24.86M(11.19M)(7.12M)
Accounts Receivables(5.55M)(36.91M)3.36M(21.09M)(58.53M)
Inventory3.22M(23.63M)(5.84M)(21.29M)(5.96M)
Accounts Payables10.17M5.04M7.55M479K15.16M
Other Working Capital(7.93M)4.2M19.79M30.71M42.21M
Other Non-Cash Items5.02M8.99M6.62M18.56M(29.57M)
Operating Cash Flow3.32M(31.2M)118.96M64.02M185.23M
Capital Expenditures(23.64M)(16.46M)(18.51M)(16.95M)(34.32M)
Acquisitions (Net)(84.49M)(33K)0(401.28M)0
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities(18.43M)(6.83M)(9.64M)12.8M(20.49M)
Investing Cash Flow(105.48M)(15.74M)(18.51M)(404.72M)(34.32M)
Debt Repayment99.02M(3M)(3M)345.22M(10.16M)
Common Stock Issued69.58M080.56M013.6M
Common Stock Repurchased(890K)(1.96M)(4.99M)(10.96M)(12.21M)
Dividends Paid(190K)(1.63M)(1.63M)(1.63M)(1.16M)
Other Financing Activities2.07M1.46M(3.5M)(67.69M)(26K)
Financing Cash Flow194.6M(5.13M)67.44M264.95M(9.94M)
Effect of Forex Changes000(470K)(233K)
Net Change in Cash92.43M(52.07M)167.89M(76.23M)140.73M
Free Cash Flow(20.32M)(47.66M)100.45M47.06M150.9M

ANI Pharmaceuticals, Inc.

NASDAQ:ANIP

Intrinsic Alpha fair value

Locked

Current Price

$71.47

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.